The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $18,055,840 in first-year total cost, median $1,562,129.
Most frequent study sections
- Special Emphasis Panel[ZEY1 VSN (01)]2
- Special Emphasis Panel[ZEY1 VSN (10)]2
- Special Emphasis Panel[ZEY1 VSN (02)]1
Most frequent institutions
- JAEB CENTER FOR HEALTH RESEARCH, INC.2
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- JOHNS HOPKINS UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | DRCR Retina Network2UG1EY014231-23 | GLASSMAN, ADAM RMARTIN, DANIEL FSUN, JENNIFER KATHERINE | JAEB CENTER FOR HEALTH RESEARCH, INC., FL | $8,942,823 | ZEY1 |
| 2024 | Pediatric Eye Disease Investigator Group Coordinating Center2UG1EY011751-28 | KRAKER, RAYMONDPINELES, STACYWEISE, KATHERINE K | JAEB CENTER FOR HEALTH RESEARCH, INC., FL | $6,016,896 | ZEY1 |
| 2023 | Parasitic Ulcer Treatment Trial1UG1EY033284-01A1 | KEENAN, JEREMY DAVID | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,562,129 | ZEY1 |
| 2023 | Glaucoma Drainage Device and Endothelial Cell Density Loss Compare (DECLARE) Trial1UG1EY033703-01A1 | HAN, YINGROSE-NUSSBAUMER, JENNIFER | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,191,591 | ZEY1 |
| 2022 | NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa1UG1EY033286-01 | CAMPOCHIARO, PETER A | JOHNS HOPKINS UNIVERSITY, MD | $342,401 | ZEY1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.